NCT00054236View on ClinicalTrials.gov

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1

BIOLOGICAL

filgrastim

Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.

DRUG

cyclophosphamide

cyclophosphamide IV over 2 hours on days -3 to -2

DRUG

fludarabine phosphate

fludarabine IV over 30 minutes on days -8 to -4

PROCEDURE

umbilical cord blood transplantation

Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.

DRUG

methylprednisolone

Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.

Trial Locations (1)

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT00054236 - Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter